From the second, independent cohort, we prospectively tested 35 women with available TUS images of OMs, serum CA-125 levels, and histopathological results treated from January 1, 2021, to April 30 2021. The gene discussed is MUC16; the disease is opsoclonus-myoclonus syndrome.